Ana Navas-Acien

Aug 14, 2024 | jamanetwork.com | Gervasio A. Lamas |Miami Beach |Kevin J. Anstrom |Ana Navas-Acien

Key PointsQuestion  Does therapy with edetate disodium (EDTA)–based chelation reduce major adverse cardiovascular events compared with placebo infusions among patients with diabetes and prior myocardial infarction (MI)? Findings  EDTA-based chelation did not reduce major adverse cardiovascular events compared with placebo infusion, with a hazard ratio of 0.93 (95% CI, 0.76-1.16; P = .53).

Aug 14, 2024 | jamanetwork.com | Gregory Curfman |Gervasio A. Lamas |Kevin J. Anstrom |Ana Navas-Acien

Edetate Disodium–Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes Gervasio A. Lamas, MD; Kevin J. Anstrom, PhD; Ana Navas-Acien, MD, PhD; Robin Boineau, MD, MA; Hayley Nemeth, MS; Zhen Huang, MS; Jun Wen, MS; Yves Rosenberg, MD, MPH; Mario Stylianou, PhD; Teresa L. Z. Jones, MD; Bonnie R. Joubert, PhD, MPH; Qilu Yu, PhD; Regina M. Santella, PhD; Ana C. Mon, MPH; Francisco Ujueta, MD, MS; Esteban Escolar, MD; David M. Nathan, MD; Vivian A. Fonseca, MD; Y.